Moffitt logo

Clinical Trials Search

Clinical Trial 19821

Cancer Type: Genitourinary
Interventions:[18]F-DCFPyL

Study Type: Diagnostic
Phase of Study: Phase III
Investigators:

  • Kenneth Gage

Call 813-745-6100
or 1-800-679-0775
Overview

Study Title

A Phase 3, Multi-Center, Open-Label Study to Assess the DiagNostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men with Suspected Recurrence of PrOstate CanceR (CONDOR)

Summary

Objective

To determine the Correct Localization Rate (CLR) of 18F-DCFPyL PET/CT imaging in the detection of recurrent prostate cancer at the subject level. To assess the impact of 18F-DCFPyL PET/CT disease detection on patients clinical management plans. To evaluate the safety and tolerability of 18F-DCFPyL. To determine detection rates of disease sites with 18F-DCFPyL PET/CT by region (prostatic, pelvic, extra-pelvic) and baseline PSA. To determine the Positive Predictive Value (PPV) of 18F-DCFPyL PET/CT imaging in the detection of recurrent disease in the prostatic, pelvic, and extra-pelvic regions.

Inclusion Criteria

  • Male >/= 18 years of age
  • Histopathologically confirmed prostate adenocarcinoma per original diagnosis, with subsequent definitive therapy
  • Suspected recurrence of prostate cancer based on rising PSA after definitive therapy on the basis of:
  • Post-radical prostatectomy: Detectable or rising PSA that is ≥ 0.2 ng/mL with a confirmatory PSA ≥ 0.2 ng/mL (American Urological Association [AUA]); or
  • Post-radiation therapy, cryotherapy, or brachytherapy: Increase in PSA level that is elevated by ≥ 2 ng/mL above the nadir (American Society for Therapeutic Radiology and Oncology [ASTRO]-Phoenix)
  • Negative or equivocal findings for prostate cancer on conventional imaging performed as part of standard of care workup within 60 days prior to Day 1
  • Life expectancy ≥6 months as determined by the investigator
  • Able and willing to provide informed consent and comply with protocol requirements

  • Exclusion Criteria

  • Subjects administered any high energy (>300 KeV) gamma-emitting radioisotope within five (5) physical half-lives prior to Day 1
  • Ongoing treatment with any systemic therapy (e.g. ADT, antiandrogen, GnRH, LHRH agonist or antagonist) for prostate cancer
  • Treatment with ADT in the past 3 months of Day 1
  • Receipt of investigational therapy for prostate cancer within 60 days of Day 1
  • Subjects with any medical condition or other circumstances that, in the opinion of the investigator, compromise the safety or compliance of the subject to produce reliable data or completing the study